REUTERS
October 21, 2021 at 16:45 JST
A COVID-19 vaccine Shionogi & Co. is jointly developing with the National Institute of Infectious Diseases and a university (Provided by Shionogi & Co.)
Japan’s Shionogi & Co. Ltd. said on Wednesday it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate.
The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The company will also prepare to conduct multiple trials globally, it said.
Medicines usually have to pass three phases of clinical trials before they can be assessed for approval by regulators.
Separately, Daiichi Sankyo Co. said it planned to start a Phase II trial for its COVID-19 vaccine candidate next month.
The Japanese drugmaker is aiming for commercialization of the mRNA-type vaccine, known as DS-5670, in 2022, it said in a statement.
Japanese vaccine using smaller dose than Pfizer, Moderna in trials
October 19, 2021
New clinical trial method speeds up Shionogi vaccine rollout
September 13, 2021
Japan’s Shionogi sells coronavirus drug rights to U.S. biotech BioAge
January 26, 2021
Indonesia green-lights emergency use of Chinese vaccine
January 12, 2021
China Sinopharm’s coronavirus vaccine taken by about a million people in emergency use
November 19, 2020Tibet Rhodiola Pharma obtains right to develop Russia’s Sputnik-V vaccine in China
November 12, 2020
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
A peek through the music industry’s curtain at the producers who harnessed social media to help their idols go global.
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series about Japanese-Americans and their memories of World War II
